Table 2.

Moderation analysis of Racial/Ethnic Discordance on Patient and Clinician Intervention on Anxiety Symptoms

Training Dosage	GAD-7 (Time 3)
	Coeff.		SE	Cohen d	p value
Racial/Ethnic Discordance
Patient Dosage		−.77	.59	−.14	.19
Clinician Dosage		−.10	.76	−.02	.89
Patient & Clinician Dosage		−4.09	1.71	−.76	.02
Discordance Coefficient		.00	.51	.00	1.00
Discordance & Patient Dosage		−.06	.99	−.01	.96
Discordance & Clinician Dosage		−2.80	1.17	−.52	.02
Discordance & Patient Dosage & Clinician Dosage		5.76	2.77	1.07	.04
Intervention joint significance test (discordance interactions)		F3, 3619.5 = 3.19			.02
Linguistic Discordance
Patient Dosage	−1.02		.55	−.19	.06
Clinician Dosage	−.91		.63	−.17	.14
Patient & Clinician Dosage	−2.22		1.50	−.41	.14
Discordance Coefficient	−.31		.57	−.06	.59
Discordance & Patient Dosage	1.27		1.06	.24	.23
Discordance & Clinician Dosage	−2.70		1.64	−.50	.10
Discordance & Patient Dosage & Clinician Dosage	3.67		2.87	.68	.20
Intervention joint significance test (discordance interactions)	F3, 3377.7 = 1.59				.19
Patient Gender
Patient Dosage	−.83		.55	−.15	.13
Clinician Dosage	−1.19		.65	−.22	.06
Patient & Clinician Dosage	−2.23		1.66	−.41	.18
Gender Main Effect (Female)	−.61		.44	−.11	.17
Female × Patient Dosage	1.26		1.18	.23	.28
Female × Clinician Dosage	−1.31		1.20	−.24	.28
Female × Patient × Clinician Dosage	3.36		3.53	.62	.34
Intervention joint significance test of all female interactions	F3, 4,388.0 = 1.01				.39

Notes:

^1.All analyses and significance tests were adjusted for multiple imputation and small sample size.

^2.Racial/ethnic discordance: Model controls for the outcome measure at baseline, patient and clinician race, and patient education level.

^3.Linguistic discordance: Model controls for the outcome measure at baseline, patient and clinician language, and patient education level.

^4.Patient gender: Model controls for the outcome measure at baseline, patient gender, and patient education level.